The most effective antipsychotic drug for people with treatment-resistant schizophrenia is clozapine. Yet, across the world, ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...

Drug-induced schizophrenia develops after substance use but is not directly the result of substance use. It is likely a combination of factors, including the substance, family history, and ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday.

The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.

Bristol Myers Squibb says the drug will be available starting in October at $1,850 a month, which is in line with other schizophrenia treatments. It's unclear how easy it will be for patients to ...

Karuna’s experimental schizophrenia drug succeeds in advanced study If approved by the FDA, the Boston biotech’s medicine would be the first new type of treatment for the disease in decades.

People with schizophrenia will have a new treatment option for the first time in more than three decades, after the Food and Drug Administration Thursday approved a new kind of drug. Studies ...

AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said. On Monday AbbVie (ABBV) said that its Phase 2 trial ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday.

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...